REGN - REGENERON PHARMACEUTICALS, INC.

QQQ $ 635.72 $ 0.00 (0 %)

DIA $ 477.83 $ 0.00 (0 %)

SPY $ 688.84 $ 0.00 (0 %)

TLT $ 91.95 $ 0.00 (0 %)

GLD $ 370.38 $ 0.00 (0 %)

Previous Close

$ 654.48

Open

$ 612.02

Bid

$ 650.02 x 9

Ask

$ 654.00 x 210

Day's Range

-- - --

52 Week Range

$ 475.76 - $ 931.87

Volume

2,126,839

Average Volume

Market Cap

68.79B

Beta (5Y Monthly)

$ 0.72

PE Ratio (TTM)

$ 15.03

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	10-28-2025	09-30-2025	10-Q
2	08-01-2025	06-30-2025	10-Q
3	04-29-2025	03-31-2025	10-Q
4	02-05-2025	12-31-2024	10-K
5	10-31-2024	09-30-2024	10-Q
6	08-01-2024	06-30-2024	10-Q
7	05-02-2024	03-31-2024	10-Q
8	02-05-2024	12-31-2023	10-K
9	11-02-2023	09-30-2023	10-Q
10	08-03-2023	06-30-2023	10-Q
11	05-04-2023	03-31-2023	10-Q
12	02-06-2023	12-31-2022	10-K
13	11-03-2022	09-30-2022	10-Q
14	08-03-2022	06-30-2022	10-Q
15	05-04-2022	03-31-2022	10-Q
16	02-07-2022	12-31-2021	10-K
17	11-04-2021	09-30-2021	10-Q
18	08-05-2021	06-30-2021	10-Q
19	05-06-2021	03-31-2021	10-Q
20	02-08-2021	12-31-2020	10-K
21	11-05-2020	09-30-2020	10-Q
22	08-05-2020	06-30-2020	10-Q
23	05-05-2020	03-31-2020	10-Q
24	02-07-2020	12-31-2019	10-K
25	11-05-2019	09-30-2019	10-Q
26	08-06-2019	06-30-2019	10-Q
27	05-07-2019	03-31-2019	10-Q
28	02-07-2019	12-31-2018	10-K
29	11-06-2018	09-30-2018	10-Q
30	08-02-2018	06-30-2018	10-Q
31	05-03-2018	03-31-2018	10-Q
32	02-08-2018	12-31-2017	10-K
33	11-08-2017	09-30-2017	10-Q
34	08-03-2017	06-30-2017	10-Q
35	05-04-2017	03-31-2017	10-Q
36	02-09-2017	12-31-2016	10-K
37	11-04-2016	09-30-2016	10-Q
38	08-04-2016	06-30-2016	10-Q
39	05-05-2016	03-31-2016	10-Q
40	02-11-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

nasdaq-100-hits-26000-gold-falls-below-4000-whats-moving-markets-tuesday

Nasdaq 100 Hits 26,000, Gold Falls Below $...
10/28/2025 17:23:51

Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump-Xi meeting, and major tech...

wayfair-qorvo-celestica-united-parcel-service-regeneron-pharmaceuticals-and-other-big-stocks-moving-higher-on-tuesday

Wayfair, Qorvo, Celestica, United Parcel S...
10/28/2025 14:14:02

regenerons-q3-earnings-outperform-expectations-with-dupixent-strength-balancing-eylea-weakness

Regeneron's Q3 Earnings Outperform Expecta...
10/28/2025 13:13:27

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea sales.

Earnings Scheduled For October 28, 2025
10/28/2025 11:11:34

Regeneron Pharmaceuticals Q3 Adj. EPS $11....
10/28/2025 10:30:38

Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $11.83 per share which beat the analyst consensus estima...

A Preview Of Regeneron Pharmaceuticals's E...
10/27/2025 15:01:00

Here's How Much $1000 Invested In Regenero...
10/20/2025 16:14:58

fda-unveils-first-experimental-drugs-under-fast-track-voucher-plan-to-cut-drug-review-times

FDA Unveils First Experimental Drugs Under...
10/17/2025 14:03:18

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, a...

Regeneron's Libtayo Wins Positive European...
10/17/2025 11:32:55

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the European Medicines Agency's (EMA) Committee for Medi...

FDA Awards First-Ever National Priority Vo...
10/16/2025 21:27:26

https://www.fda.gov/news-events/press-announcements/fda-awards-first-ever-national-priority-vouchers-nine-sponsors

eyepoint-pharmaceuticals-raises-capital-as-it-advances-lead-product-to-pivotal-study

EyePoint Pharmaceuticals Raises Capital As...
10/15/2025 15:01:34

EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding.

Regeneron to Share New Oncology Data at ES...
10/15/2025 11:04:44

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced new and updated data from its advancing oncology pipeline will be...

Canaccord Genuity Maintains Buy on Regener...
10/14/2025 14:10:31

Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and maintains $850 price ...

regenerons-gene-therapy-shows-significant-gains-in-genetic-hearing-loss

Regeneron's Gene Therapy Shows Significant...
10/13/2025 17:24:21

Regeneron gene therapy for OTOF-related hearing loss shows rapid, sustained improvements, including normal hearing in some part...

Citigroup Maintains Buy on Regeneron Pharm...
10/13/2025 15:57:14

Citigroup analyst Geoff Meacham maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target fro...

Reported Sunday, Regeneron's DB-OTO Gene T...
10/13/2025 06:39:46

Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal ...

Forecasting The Future: 9 Analyst Projecti...
10/10/2025 18:01:09

Morgan Stanley Maintains Overweight on Reg...
10/10/2025 17:24:28

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and lowers the p...

regenerons-libtayo-gains-fda-approval-to-reduce-recurrence-risk-in-skin-cancer-patients

Regeneron's Libtayo Gains FDA Approval To ...
10/09/2025 17:59:58

FDA approves Regeneron's Libtayo for adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation, b...

Regeneron Pharma Says FDA Approves PD-1 In...
10/08/2025 18:33:42

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by...

Notes From The Street: 'FLASHBACK....Oil G...
01/13/2015 13:20:41